The ASPIRE Trial - understanding the impact of mucositis on cachexia in head and neck cancer

Not Applicable

• Conditions: head and neck cancer; mucositis; cachexia; Cancer - Head and neck; Inflammatory and Immune System - Other inflammatory or immune system disorders; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12623000521628
• Lead Sponsor: niversity of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-19
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

>18 years of age
Stage III and IV oropharyngeal and hypopharyngeal/laryngeal carcinoma treated with definitive chemoradiation
Scheduled to receive definitive intensity modulated radiotherapy + cisplatin-based chemotherapy

Exclusion Criteria

Patients treated with systemic therapy other than cisplatin

Study & Design

• Study Type: Observational
• Study Design: Not specified